Obesity is a well-established driver of insulin resistance and cardiorenal risk, and SGLT2 inhibitors exert multiple favorable metabolic effects—including weight loss, blood pressure reduction, and natriuresis—that may be especially beneficial in this population. This evidence concerns the gene SLC5A2 and obesity disorder.